The Global Minimally Invasive Biopsy Technologies Market is projected to reach USD 3.98 billion in 2027. The market is anticipated to be driven by the increased use of minimally invasive surgical techniques in biopsy testing and a sharp increase in the incidence of breast and lung cancers worldwide. In North America, minimally invasive breast biopsies account for about 66% of all initial breast biopsies (MIBB).In individuals with worrisome or ambiguous breast lesions, a sizable portion of the overall open excisional biopsy has been replaced with a minimally invasive biopsy technique. Higher precisions can be attained using minimally invasive procedures for the biopsy, which in turn helps to lessen the psychological toll that patients experience and also significantly lowers the overall cost.
increased need for biopsy testing to diagnose malignant cells, identify infectious, autoimmune, and inflammatory conditions, as well as the widespread growth of less invasive surgical techniques. The continuous drivers of this market have been early cancer detection and improved precision compared to incisional and excisional biopsies.
The COVID-19 pandemic hurts market expansion. Breast cancer biopsy services suffered a lot of unfavorable effects from the epidemic. Hospitals, clinics, and diagnostic centers were unable to provide biopsy services due to lockdowns in various countries to stop the spread of COVID-19. An investigation into the effects of COVID-19-related cancer diagnosis delays was conducted in the UK and reported in The Lancet Oncology in March 2021. Over 100,000 patients with breast, colorectal, esophageal, or lung cancer were included in the study. The study discovered that the pandemic is expected to significantly lower 1- and 5-year cancer survival rates due to the lack of screening services.
Further key findings from the report suggest :
With a proven track record of providing high-quality treatment, ambulatory surgical facilities offer a more practical outpatient procedure alternative to hospital-based inpatient systems. Ambulatory surgery centers, which include all necessary and contemporary MIB technologies, are anticipated to experience the quickest growth among the end-use verticals throughout the projected period.
Lung cancer, breast cancer, prostate cancer, colorectal cancer, blood cancer, and non-oncology application are further subgroups of the therapeutic application. Worldwide, minimally invasive breast biopsy (MIBB) has been strongly advised for pre-breast cancer diagnosis and examination. As more women develop breast cancer during the forecast period, the MIBB is anticipated to grow faster.
Due to its significant increase in breast and lung cancer cases as well as increased adoption of MIB technologies, the Asia Pacific area is anticipated to expand at the fastest rate, or 20.1%, from 2020 to 2027.
Key players in the market include Chronix Biomedical, Biocept, Inc., F. Hoffmann-La Roche Ltd, Mauna Kea Technologies, Veracyte, Inc., Thermo Fisher Scientific, NeoGenomics Laboratories, Inc., Abcodia Ltd., Adaptive Biotechnologies, and Owlstone Medical Ltd., among others.
For this report, Emergen Research has segmented the global Minimally Invasive Biopsy Technologies Market based on Technology, Therapeutic Application, End-Use Verticals, and region:
Technology Outlook (Revenue: USD Billion; 2017-2027)
- Liquid Biopsy
- Optical Biopsy
- Brush Biopsy
- Pigmented Lesion Assays
- Breath Biopsy
- Brush Biopsy
Therapeutic Application Outlook (Revenue: USD Billion; 2017-2027)
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Blood Cancer
- Non-oncology Applications
End-Use Verticals Outlook (Revenue: USD Billion; 2017-2027)
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Cancer Research Institutes
Regional Outlook (Revenue: USD Billion; 2017-2027)
- North America
- the U.S.
- the UK
- the Asia Pacific
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Saudi Arabia
- Rest of MEA
To get leading market solutions, Visit the Link